|
|
Volumn 45, Issue 3, 2018, Pages 405-410
|
|
Pomalidomide in patients with interstitial lung disease due to systemic sclerosis: A phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
a
|
|
Author keywords
Clinical trials; Disease activity; Disease modifying antirheumatic drugs; Interstitial lung disease; Systemic sclerosis
|
|
Indexed keywords
C REACTIVE PROTEIN;
PLACEBO;
POMALIDOMIDE;
IMMUNOLOGIC FACTOR;
THALIDOMIDE;
ADULT;
AGED;
ARTHRALGIA;
ARTICLE;
BRONCHITIS;
CLINICAL ARTICLE;
CONSTIPATION;
CONTROLLED STUDY;
DIARRHEA;
DIFFUSE SCLERODERMA;
DISEASE ASSOCIATION;
DOUBLE BLIND PROCEDURE;
DRUG EFFICACY;
DRUG SAFETY;
DRUG TOLERABILITY;
FEMALE;
FORCED VITAL CAPACITY;
HEADACHE;
HUMAN;
INFECTION;
INFESTATION;
INFORMED CONSENT;
INTERSTITIAL LUNG DISEASE;
KIDNEY FAILURE;
LIMITED SCLERODERMA;
LUNG EMBOLISM;
MALE;
MODIFIED RODNAN SKIN SCORE;
MULTICENTER STUDY;
OPEN STUDY;
PHASE 2 CLINICAL TRIAL;
PNEUMONIA;
PRIORITY JOURNAL;
PROTEIN BLOOD LEVEL;
RANDOMIZED CONTROLLED TRIAL;
RASH;
SCORING SYSTEM;
SIDE EFFECT;
SKIN TOXICITY;
SPRAIN;
UPPER RESPIRATORY TRACT INFECTION;
CLINICAL TRIAL;
COMPLICATION;
DRUG EFFECT;
EARLY TERMINATION OF CLINICAL TRIAL;
FIBROSIS;
FOLLOW UP;
FORCED EXPIRATORY VOLUME;
LUNG;
MIDDLE AGED;
PATHOLOGY;
SKIN;
SYSTEMIC SCLEROSIS;
TREATMENT OUTCOME;
VITAL CAPACITY;
ADULT;
DOUBLE-BLIND METHOD;
EARLY TERMINATION OF CLINICAL TRIALS;
FEMALE;
FIBROSIS;
FOLLOW-UP STUDIES;
FORCED EXPIRATORY VOLUME;
HUMANS;
IMMUNOLOGIC FACTORS;
LUNG;
LUNG DISEASES, INTERSTITIAL;
MALE;
MIDDLE AGED;
SCLERODERMA, SYSTEMIC;
SKIN;
THALIDOMIDE;
TREATMENT OUTCOME;
VITAL CAPACITY;
|
|
EID: 85042691379
PISSN: 0315162X
EISSN: 14992752
Source Type: Journal
DOI: 10.3899/jrheum.161040 Document Type: Article |
|
Times cited : (32)
|
|
References (11)
|
